Payment overview · 2025
General Payments
$27,152.99
44 reported records · 8 companies
Healthcare provider profile · identity verified
David E Kandzari, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · ATLANTA, GA · NPI 1871677930
Verified facts
What the public records show
CMS Open Payments records show David E Kandzari, MD received $27,152.99 in general payments during 2025 across 44 reported records.
Medtronic, Inc. accounted for 73.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nexletol.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexletol by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19,892.61 | 73.3% | 28 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $4,795.61 | 17.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,694.28 | 6.2% | 7 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $500.00 | 1.8% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $191.40 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.53 | 0.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.07 | 0.1% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $20.49 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,544.40 | 6 |
| Consulting Fee | $8,346.91 | 3 |
| Travel and Lodging | $2,540.27 | 10 |
| Food and Beverage | $1,721.41 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $18,193.65 | 12 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTA Normalized: selution slr pta |
Device | CORDIS US CORP. | $3,381.90 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $1,443.26 | 3 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $191.40 | 1 | 2025 |
Source payment records
|
|||||
| ONYX 18 Normalized: onyx 18 |
Device | Medtronic, Inc. | $128.43 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $100.70 | 2 | 2025 |
Source payment records
|
|||||
| Vitalyst Normalized: vitalyst |
Device | Boston Scientific Corporation | $89.34 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $60.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $20.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 22 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 398 | 134 |
| Clopidogrel | Clopidogrel Bisulfate | 388 | 145 |
| Ezetimibe | Ezetimibe | 193 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 163 | 60 |
| Losartan Potassium | Losartan Potassium | 136 | 40 |
| Nifedipine Er | Nifedipine | 107 | 39 |
| Eliquis | Apixaban | 84 | 22 |
| Lisinopril | Lisinopril | 82 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 57 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 20 |
| Prasugrel Hcl | Prasugrel Hcl | 52 | 18 |
| Ranolazine Er | Ranolazine | 49 | 14 |
| Carvedilol | Carvedilol | 44 | 17 |
| Nitroglycerin | Nitroglycerin | 36 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27,152.99 · 44 records | Medtronic, Inc. | AVVIGO Guidance System, ELIQUIS, General - Therapies, General - Vascular Access, NEXLETOL, ONYX 18, SELUTION SLR PTA, SYMPLICITY G3, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Vitalyst | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error